Exelixis (NASDAQ:EXEL – Get Free Report) had its price target increased by investment analysts at JMP Securities from $47.00 to $50.00 in a report issued on Monday,Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology comp…